{
    "root": "30b2d961-719f-5936-e063-6294a90adf08",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Venlafaxine Hydrochloride",
    "value": "20250319",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "VENLAFAXINE HYDROCHLORIDE",
            "code": "7D7RX5A8MO"
        }
    ],
    "indications": "venlafaxine extended release tablets selective serotonin norepinephrine reuptake inhibitor ( snri ) indicated : major depressive disorder ( mdd ) ( 1.1 ) social anxiety disorder ( sad ) ( 1.2 )",
    "contraindications": "venlafaxine extended release tablets administered single dose food either morning evening approximately time day . tablet swallowed whole fluid divided , crushed , chewed , placed water .",
    "warningsAndPrecautions": "venlafaxine extended release tablets 75 mg round , biconvex , white coated tablets os302 printed one side . supplied follows : ndc : 70518-2587-00 ndc : 70518-2587-01 packaging : 90 1 bottle plastic packaging : 90 1 bottle plastic store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15-30\u00b0c ( 59-86\u00b0f ) [ usp controlled room temperature ] . protect moisture humidity . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "serotonin syndrome maois : maoi \u2019 intended treat psychiatric disorders venlafaxine extended release tablets within 7 days stopping treatment venlafaxine extended release tablets . venlafaxine extended release tablets within 14 days stopping maoi intended treat psychiatric disorders . addition , start venlafaxine extended release tablets patient treated linezolid intravenous methylene blue ( 4.1 ) .",
    "indications_original": "Venlafaxine Extended Release Tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 )",
    "contraindications_original": "Venlafaxine Extended Release Tablets should be administered in a single dose with food either in the morning or in the evening at approximately the same time each day. Each tablet should be swallowed whole with fluid and not divided, crushed, chewed, or placed in water.",
    "warningsAndPrecautions_original": "Venlafaxine Extended Release Tablets 75 mg are round, biconvex, white coated tablets with OS302 printed on one side. They are supplied as follows:\n                  NDC: 70518-2587-00\n                  NDC: 70518-2587-01\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15-30\u00b0C (59-86\u00b0F)\u00a0[see USP Controlled Room Temperature]. Protect from moisture and humidity.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Serotonin Syndrome and MAOIs:\u00a0 Do not use MAOI\u2019s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets.\u00a0 Do not use Venlafaxine Extended Release Tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders.\u00a0 In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with \u00a0linezolid or intravenous methylene blue ( 4.1 )."
}